Aktienanalyse zu Innoviva Inc (INVA)INVAInnoviva Inc

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Innoviva Inc is a good buy right now due to its current price of $20.78 being significantly below the analyst price targets of $34 to $42, indicating substantial upside potential. The company has a strong forward P/E ratio of 8.54, suggesting it is undervalued compared to its earnings potential. However, a risk to consider is the recent Q2 loss of $83.4 million, which may affect investor sentiment.